FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS

被引：0
|
作者：
Masi, G. [1 ]
Vasile, E. [1 ]
Loupakis, F. [1 ]
Cupini, S. [2 ]
Fornaro, L. [1 ]
Baldi, G. [2 ]
Salvatore, L. [1 ]
Stasi, I [1 ]
Brunetti, I [3 ]
Ricci, S. [3 ]
Palazzo, A. [4 ]
Pellegrino, A. [4 ]
Truscelli, K. [4 ]
Garrone, M. [5 ]
Chiara, S. [6 ]
Ribecco, A. [7 ]
Crino, L. [8 ]
Andreuccetti, M. [1 ]
Falcone, A. [1 ,2 ]
机构：
[1] Ist Toscano Tumori, Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Ist Toscano Tumori, UO Oncol Med, Azienda USL Livorno 6, Livorno, Italy
[3] Ist Toscano Tumori, UO Oncol Med 1, Azienda Osped Univ Pisana, Pisa, Italy
[4] Univ Roma La Sapienza, UO Oncol B, Dipartimento Med Sperimentale, Rome, Italy
[5] Osped S Croce Carle, UO Oncol Med, Cuneo, Italy
[6] Ist Nazl Tumori, UO Oncol Med, Genoa, Italy
[7] Ist Toscano Tumori, Azienda Sanit Firenze, SC Oncol Med, Florence, Italy
[8] Osped S Andrea delle Fratte, UO Oncol Med, Perugia, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer
    Trarbach, T.
    Schuette, K.
    Stoehlmacher, J.
    Goekkurt, E.
    Guenther, H.
    Ubbelohde, U.
    Stroszczynski, C.
    Ehninger, G.
    Folprecht, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
    de Gramont, A.
    Boni, C.
    Navarro, M.
    Tabernero, J.
    Hickish, T.
    Topham, C.
    Bonetti, A.
    Clingan, P.
    Lorenzato, C.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)
    Bennouna, J.
    Liedo, G.
    Ychou, M.
    Conroy, T.
    Hebbar, M.
    Adenis, A.
    Paillot, B.
    Faroux, R.
    Douillard, J.
    Ducreux, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 179 - 180
  • [34] SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.
    Samson, B.
    Latreille, J.
    Nguyen, N. T.
    Sperlich, C.
    Berbiche, D.
    Tournigand, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] Randomized trial of either UFT or infusional 5-FU in combination with Erbitux, oxaliplatin and folinic acid in first-line treatment of metastatic colorectal cancer
    Rolski, J.
    Barone, C.
    Schaberl-Moser, R.
    Eggleton, S.
    Douillard, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 28
  • [36] Updated results of the FIRIS study: A phase II/III trial of 5FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC)
    Baba, H.
    Muro, K.
    Yasui, H.
    Shimada, Y.
    Tsuji, A.
    Sameshima, S.
    Satoh, T.
    Denda, T.
    Ina, K.
    Sugihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial
    Ychou, M.
    Desseigne, F.
    Guimbaud, R.
    Ducreux, M.
    Bouche, O.
    Becouarn, Y.
    Adenis, A.
    Montoto-Grillot, C.
    Luporsi, E.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Folfoxiri compared to folfiri as first-line treatment of metastic colorectal cancer (MCRC): Updated results, multivariate and subgroups analisys of the GONO randomized phase III study
    Falcone, A.
    Andreuccetti, M.
    Ricci, S.
    Orlandini, C.
    Barbara, C.
    Evangelista, W.
    Ciuffreda, L.
    Cortesi, E.
    Ferraldeschi, R.
    Chiara, S.
    Granetto, C.
    Loupakis, F.
    Bursi, S.
    Allegrini, G.
    Masi, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII28 - VII28
  • [39] FOLFOXIRI improves survival compared to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC):: Updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (GONO)
    Masi, G.
    Barbara, C.
    Brunetti, I
    Pfanner, E.
    Murr, R.
    Ricci, S.
    Benedetti, G.
    Crino, L.
    Evangelista, W.
    Bertetto, O.
    Picone, V
    Cortesi, E.
    Vitello, S.
    Chiara, S.
    Granetto, C.
    Merlano, M.
    Fioretto, L.
    Orlandini, C.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI3 - XI4
  • [40] Randomised comparison of 5-FU/folinic acid plus irinotecan (FOLFIRI) and irinotecan plus oxaliplatin (IROX) in first-line therapy of metastatic colorectal cancer (CRC):: the fire-trial
    von Weikersthal, L. Fischer
    Schalhorn, A.
    Quietzsch, D.
    Maubach, P. A.
    Schlimok, G.
    Lambertz, H.
    Weigang-Koehler, K.
    Schultz, M.
    Schlag, R.
    Grundeis, M.
    Heinemann, V.
    EJC SUPPLEMENTS, 2005, 3 (02): : 167 - 167
12345